NDANASALPOWDER
Approved
Apr 2025
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
5/8 — Partial
ATZUMI (dihydroergotamine mesylate) by Satsuma Pharmaceuticals is 5-ht 1dα and 5-ht 1dβ receptors. First approved in 2025.
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ATZUMI is a nasal powder formulation of dihydroergotamine mesylate, a 5-HT1D receptor agonist approved April 2025 for acute migraine treatment. It works by constricting cranial blood vessels and inhibiting neuropeptide release at the 5-HT1D receptor sites. The product represents a novel delivery route for an established migraine therapeutic class.
Growth15.1 years to LOE
Early-stage growth product with 15+ years of patent protection; team expansion likely as market penetration increases post-launch.
Mechanism of Action
5-HT 1Dα and 5-HT 1Dβ receptors. The therapeutic activity of dihydroergotamine in migraine is generally attributed to the agonist effects at 5-HT 1D receptors.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Pharmacodynamic Study to Compare Acute Effects of Dihydroergotamine Mesylate (DHE) on Pulmonary Arterial Pressure
Started Mar 2010
24 enrolled
Healthy
Career Relevance
ATZUMI represents a high-opportunity career entry point for professionals in brand launch and growth-stage commercial roles; Satsuma as a focused specialty pharma sponsor typically maintains lean, high-impact teams with direct visibility to product economics. Early-stage market penetration phase (2025 onward) will require intensive field force engagement, payer negotiations, and clinical education positioning.
Brand Manager
Worked on ATZUMI at Satsuma Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.